site stats

Dyne therapeutics investors

WebMar 26, 2024 · When Dyne Therapeutics last reported its balance sheet in December 2024, it had zero debt and cash worth US$256m. In the last year, its cash burn was US$157m. Therefore, from December 2024 it had roughly 20 months of cash runway. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces … WebAug 10, 2024 · Dyne Therapeutics today announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital. Contacts Stephanie Simon Ten Bridge Communications (617 ...

Investors & Media Dyne Therapeutics, Inc.

WebNX-13. NX-13 is an oral NLRX1 agonist for the treatment of Ulcerative Colitis and Crohn’s Disease. NX-13’s bimodal mechanism of action aims to decrease reactive oxygen … WebMar 20, 2024 · The Investor Relations website contains information about Dyne Therapeutics, Inc.'s business for stockholders, potential investors, and financial … Mar 10, 2024: 8-K: Report of unscheduled material events or corporate event. … The Investor Relations website contains information about Dyne Therapeutics, … Amy Reilly. Senior Vice President, Corporate Communications & Investor … The Investor Relations website contains information about Dyne Therapeutics, … hint or clue https://delozierfamily.net

Dyne Therapeutics (DYN) Price To Free Cash Flow - Zacks.com

WebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving … WebApr 13, 2024 · Aurinia Pharmaceuticals Inc (AUPH) stock is trading at $11.20 as of 3:06 PM on Thursday, Apr 13, a rise of $0.16, or 1.5% from the previous closing price of $11.03. The stock has traded between $11.04 and $11.49 so far today. Volume today is less active than usual. So far 1,641,446 shares have traded compared to average volume of 3,314,036 … WebJan 18, 2024 · Dyne Therapeutics (DYN-5.97%) saw its shares slump 18.1% on Tuesday. The biotech stock closed on Friday at $9.29 a share, then opened on Tuesday at $7.82, falling to a new 52-week low of $7.61 in ... home remedies for black spots on skin

Dyne Therapeutics to Present at Upcoming Investor Conferences

Category:Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus …

Tags:Dyne therapeutics investors

Dyne therapeutics investors

Dyne Therapeutics Announces Presentations on its DM1 and …

WebMar 20, 2024 · About Dyne Therapeutics. ... Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203. Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938 .

Dyne therapeutics investors

Did you know?

WebApr 11, 2024 · A high-level overview of Dyne Therapeutics, Inc. (DYN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and … WebNov 3, 2024 · WALTHAM, Mass., Nov. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2024 and business …

WebApr 11, 2024 · Finally, Tower Research Capital LLC TRC boosted its stake in Dyne Therapeutics by 425.0% in the third quarter. Tower Research Capital LLC TRC now owns 9,582 shares of the company's stock valued at $122,000 after buying an additional 7,757 shares in the last quarter. Institutional investors own 85.50% of the company's stock. … WebMar 20, 2024 · Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203. Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938 ...

WebApr 13, 2024 · Institutional and Insider Ownership. 12.1% of Quoin Pharmaceuticals shares are held by institutional investors. Comparatively, 11.5% of Nyxoah shares are held by … WebMar 20, 2024 · Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases. About DYNE-101 and the ACHIEVE Trial. DYNE-101 is an investigational therapeutic being evaluated in the Phase 1/2 global ACHIEVE trial, for people living with myotonic dystrophy type 1 (DM1).

WebMar 23, 2024 · Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203 Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938 …

WebApr 13, 2024 · Dyne Therapeutics Inc (DYN) stock is trading at $8.97 as of 3:43 PM on Thursday, Apr 13, a gain of $0.44, or 5.19% from the previous closing price of $8.53. The stock has traded between $8.49 and $9.15 so far today. Volume today is 467,568 compared to average volume of 400,449. home remedies for blemishes on faceWebMar 20, 2024 · Investors Dyne Therapeutics Amy Reilly [email protected] 857-341-1203. Media Dyne Therapeutics Stacy Nartker [email protected] 781-317-1938 ... hint orange waterWebLandos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune disease. … home remedies for blocked nose in infantsWebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving average of $12.09. The firm has a market ... home remedies for blepharitisWebMar 7, 2024 · WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in virtual … hint or clue 10 lettersWebMar 21, 2024 · Information Security Analyst Co-Op. Dyne Therapeutics. Waltham, MA. Posted: March 16, 2024. Full-Time. Company Overview: Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary … home remedies for bloated stomach in dogsWebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. ... Investors Dyne ... hintotex cc